The Next News

// technology and science news, explained

ScienceNews3 mins read2 sources

EU authorizes daraxonrasib for metastatic pancreatic cancer after a fast-tracked review

The November 17 decision covers previously treated adults with metastatic pancreatic cancer. In the main trial, median survival was 12.4 months vs 6.7.

By Science Desk ·

The European Commission granted EU marketing authorization on Tuesday, November 17, 2026, for daraxonrasib, a new treatment for metastatic pancreatic cancer, for adults who have already had at least one previous round of treatment. The European Medicines Agency (EMA), which reviewed the oral medicine under the name Rasonque, describes the condition as pancreatic adenocarcinoma that has spread. For patients whose disease has progressed after earlier treatment, the agency says, the outlook is poor and there are few treatment options.

The decision follows a recommendation by EMA's human medicines committee, the CHMP, which EMA announced on October 15. EMA names Revolution Medicines as the applicant, and the medicine was designated an orphan medicinal product for pancreatic cancer on April 20, 2026.

What the trial showed

The committee's view rests on an open-label, multinational phase 3 study of 500 patients whose metastatic pancreatic adenocarcinoma had worsened after earlier systemic treatment. Of those patients, 92% had a confirmed RAS G12 mutation, a group that includes the most common RAS mutations in the disease, according to EMA. Patients on daraxonrasib were compared with patients on chemotherapy.

Main results of the phase 3 study, as reported by EMA on October 15, 2026
MeasureDaraxonrasibChemotherapyData collected up to
Median overall survival12.4 months6.7 monthsJune 15, 2026
Median time without the disease worsening7.2 months3.6 monthsFebruary 10, 2026

By our arithmetic, median survival was 5.7 months longer on the drug, and the median time before the disease worsened was twice as long. The most common side effects EMA lists are diarrhea, rash, inflammation of the lining of the mouth (stomatitis), nausea and vomiting.

Daraxonrasib belongs to a class called RAS inhibitors. RAS proteins help control cell growth and survival, and in pancreatic adenocarcinoma, mutations in the RAS gene leave them permanently switched on, so cancer cells grow out of control. EMA says the drug binds to a protein called cyclophilin A, and the resulting complex attaches to RAS proteins and blocks their activity, killing cancer cells and slowing the cancer's growth.

A shorter review

EMA picked daraxonrasib as a high-priority medicine under its Cancer Medicines Pathfinder project, and its committee began a phased review in early July 2026, several months before the complete application was expected, taking the company's quality, non-clinical and clinical data in stages as they came in. EMA said in October that this shortened the assessment to less than 150 days. On November 17 the Commission put the time to EMA's positive assessment at just over 100 days, which it called nearly half the previous legal deadline of 210 days. A standard evaluation can take up to 210 active days and usually takes around a year overall, including the time a company needs to answer questions, according to EMA.

The Commission linked the procedure to the accelerated routes foreseen under the EU's pharmaceutical reform, and EMA said the lessons will help shape how phased reviews are used under the new legislation. It said it would consider other medicines for phased review case by case, where they are likely to meet an unmet medical need.

From authorization to patients

An EU authorization does not by itself bring the medicine to patients. Decisions on price and reimbursement are taken by each member state, which considers the medicine's potential role in its national health system, EMA notes. Daraxonrasib is also undergoing a joint clinical assessment under the EU's health technology assessment rules, in which member states evaluate a medicine's clinical benefits together; the Commission says the report is being accelerated so that it is available in December, to help access across the EU.

The Commission said the text of its decision would be published online soon. EMA is the official source for the medicine's assessment, and its October announcement sets out the committee's findings.

Sources

  1. Daily News 17/11/2026: Commission authorises treatment for metastatic pancreatic cancer to address an unmet medical need (MEX/26/2471) European Commission ec.europa.eu
  2. EMA recommends authorisation of Rasonque for metastatic pancreatic cancer European Medicines Agency ema.europa.eu

Checked against the 2 sources above on November 18, 2026. Spotted an error? Tell us.